China Diabetes Care Drugs And Devices Market Size and Share

China Diabetes Care Drugs And Devices Market (2025 - 2030)

China Diabetes Care Drugs And Devices Market Analysis by Mordor Intelligence

China diabetes care drugs and devices market size in 2026 is estimated at USD 9.48 billion, growing from 2025 value of USD 8.98 billion with 2031 projections showing USD 12.41 billion, growing at 5.53% CAGR over 2026-2031. Sustained growth reflects three structural forces: a diabetes population of 140-233 million people, a strong policy push for digital chronic-disease management, and rapid device innovation that augments traditional pharmacotherapy. National Volume-Based Procurement (NVBP) has lowered median insulin prices by 42.08%, unlocking USD 2.85 billion in cumulative savings and expanding access while compelling manufacturers to pursue cost-efficient, differentiated pipelines. Regulatory momentum is equally visible, with 228 novel diabetes filings cleared by the National Medical Products Administration in 2024, including the first ultra-long-acting oral hypoglycemic agent cofrogliptin. Geographic imbalances persist: tier-1 cities capture the earliest uptake of cutting-edge therapies, whereas pharmacy build-outs in tier-2/3 cities underpin the next demand wave.

Key Report Takeaways

  • By product type, drugs led with 62.85% revenue share in 2025; devices are set to grow the fastest at a 6.28% CAGR through 2031.  
  • By diabetes type, type 2 accounted for 90.55% of the China diabetes care drugs and devices market share in 2025, while type 1 is projected to advance at a 6.31% CAGR to 2031.  
  • By age group, adults held 60.72% of the China diabetes care drugs and devices market size in 2025; the geriatric segment shows the highest expansion pace at 6.18% CAGR until 2031.  
  • By distribution channel, offline outlets retained 71.65% share in 2025, yet online channels are forecast to register a 6.42% CAGR through 2031.

Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.

Segment Analysis

By Product Type: Devices Drive Innovation Despite Drug Dominance

The pharmaceutical segment captured 62.85% of 2025 revenue, confirming its primacy in the China diabetes care drugs and devices market. Yet device revenue is projected to rise faster at a 6.28% CAGR as patients and physicians converge on continuous glucose monitoring and automated delivery systems. CGM adoption has broadened from clinical users to wellness enthusiasts, while insulin pumps progress toward hybrid closed-loop integration.

Monitoring equipment maintains volume leadership; self-monitoring blood glucose meters dominate unit sales but face commodity pricing, whereas CGMs command premium price bands for real-time data feeds. Insulin innovations such as once-weekly Ico Insulin, cleared in 2024, illustrate convergence between long-acting drugs and device ecosystems. GLP-1 injectables, leveraging dual diabetes-obesity indications, are the fastest-growing non-insulin category, supported by strategic licensing moves worth over USD 2 billion each from Novo Nordisk and Merck. This cross-pollination indicates the China diabetes care drugs and devices market size for devices is escalating in tandem with next-generation pharmacotherapy.

China Diabetes Care Drugs And Devices Market: Market Share by Product Type, 2025
China Diabetes Care Drugs And Devices Market: Market Share by Product Type, 2025

By Diabetes Type: Type 1 Acceleration Amid Type 2 Dominance

Type 2 remains the volume anchor with 90.55% of 2025 revenue, driven by sedentary lifestyles and dietary transitions. Digital platforms now merge lifestyle coaching with medication adherence, expanding preventive care access across every tier-city cohort. Continuous remote coaching programs have improved HbA1c control, reinforcing device and drug adherence concurrently.

Type 1 revenue, though smaller, is forecast to grow 6.31% annually, lifted by better diagnostics and broader adult onset recognition. Clinical trials show pump therapy lowers HbA1c to 7.19% compared with 7.71% for multiple injections, underscoring superior glycemic stability. Premium per-patient spending means this cohort drives technological alpha for the China diabetes care drugs and devices market size, with spill-over benefits for type 2 care via shared CGM platforms.

By Age Group: Geriatric Surge Reshapes Care Models

Adults aged 18-64 generated 60.72% of 2025 sales, mirroring diabetes prevalence peaks; nonetheless, the ≥ 65 segment is expanding at 6.18% per year, reflecting population ageing. Cognitive decline and poly-pharmacy risks demand simplified regimens—once-weekly basal insulin and user-friendly CGMs—that fit geriatric limitations.

Guidelines published in 2024 call for personalized targets; digital interfaces now incorporate larger icons and voice prompts to enhance senior usability. Younger adults are the most tech-literate cohort, fueling early adoption of app-linked glucometers and remote consultations. Tailored product design across age strata is emerging as a competitive differentiator in the China diabetes care drugs and devices market.

China Diabetes Care Drugs And Devices Market: Market Share by Age Group, 2025
China Diabetes Care Drugs And Devices Market: Market Share by Age Group, 2025

By Distribution Channel: Digital Transformation Accelerates

Offline venues controlled 71.65% of 2025 turnover, yet online platforms are forecast to advance 6.42% per year as policy reforms permit e-pharmacy sale of prescription antidiabetics. Brick-and-mortar pharmacies remain indispensable in tier-3 cities, where personal counselling is valued and digital bandwidth can be limited.

E-commerce giants have invested in cold-chain and last-mile delivery that preserve insulin integrity; WeChat mini-programs link physician consultations, lab data, and doorstep fulfillment in a single workflow. Hybrid models integrating community pharmacists into digital ecosystems improve adherence monitoring, creating omnichannel synergies that propel growth of the China diabetes care drugs and devices market.

Geography Analysis

Regional performance diverges sharply. Tier-1 hubs—Beijing, Shanghai, Guangzhou—benefit from dense specialist clusters, premium insurance coverage, and early inclusion in NRDL pilots, forming the initial launchpad for novel drugs and sensors. Inter-city patient mobility within the Beijing-Tianjin-Hebei corridor eases some accessibility gaps, though intra-city transport still restricts clinic visits for low-income patients.

Tier-2 and tier-3 cities account for the highest incremental demand thanks to an expanding middle class and ongoing hospital and pharmacy expansions. The National Health Commission’s 2024 directive to broaden primary-care drug distribution targets these municipalities, with a 2027 deadline for chronic-disease coverage. Retail-pharmacy chains are also moving into suburban belts, supplying insulin and CGM consumables while offering diabetes educator services. Capitation pilots in rural counties have cut uncontrolled-diabetes rates and set templates for country-wide rollout.

Rural zones face specialist shortages and weaker digital infrastructure, compelling use of simplified, low-maintenance devices and SMS-based adherence tools. Government-sponsored telemedicine platforms bridge the gap by enabling county-level clinics to consult urban endocrinologists. Pending 5G network upgrades aim to support real-time CGM data streams, which would unlock latent demand and further balance regional inequities in the China diabetes care drugs and devices market.

Regulatory Landscape

China diabetes care drug and device regulation is anchored by the National Medical Products Administration (NMPA) for product registration, clinical evaluation, and post-market surveillance, while pricing and access are shaped by national reimbursement and procurement mechanisms. Under NVBP, reported median insulin prices fell by 42.08%, with USD 2.85 billion in cumulative savings, reinforcing a volume-driven environment for cost-efficient supply and local manufacturing.

On the compliance side, policy updates in 2025-2026 strengthen lifecycle oversight for advanced device categories and tighten quality requirements across drug and device manufacturing. NMPA measures released in 2025 (No. 63, 2025) emphasize optimized lifecycle regulation for high-end medical devices (including AI-enabled technologies), and revisions to the Regulations on the Implementation of the Drug Administration Law took effect on May 15, 2026. Separately, revised Regulations for the Supervision and Administration of Medical Device Manufacturing take effect on Nov 1, 2026, increasing the focus on manufacturing quality management, which is particularly relevant for CGM sensors, insulin delivery systems, and combination-product supply chains.

Competitive Landscape

Foreign incumbents Abbott, Medtronic, and Novo Nordisk continue to command mind-share through breakthrough hardware and biologics portfolios. However, consistent NRDL deflation prompts margin realignment, encouraging joint ventures and technology transfers that localize production. Novo Nordisk’s USD 2 billion acquisition of United Laboratories’ obesity asset UBT251 exemplifies portfolio broadening into adjacent metabolic domains.

Domestic innovators are rapidly scaling. Sinocare’s exclusive European distribution pact for its third-generation CGM reflects international validation of Chinese engineering. Regulatory measures now prioritise local inventions within procurement, granting accelerated review to home-grown GLP-1 analogs and non-invasive glucometers. Hengrui’s USD 400 million licence-in of a US GLP-1 candidate further illustrates capital inflows to domestic R&D.

Competitive differentiation is shifting toward integrated ecosystems that combine drugs, devices, and data services into seamless user journeys. The Abbott-Medtronic linkage of FreeStyle Libre sensors with automated pumps underscores movement toward closed-loop platforms. Providers capturing rural expansion and geriatric service niches are likely to outpace rivals focused solely on urban hospital channels, setting the strategic trajectory for the China diabetes care drugs and devices market.

China Diabetes Care Drugs And Devices Industry Leaders

  1. Medtronics

  2. Roche

  3. NovoNordisk

  4. Sanofi

  5. Abbott Laboratories

  6. *Disclaimer: Major Players sorted in no particular order
China Diabetes Drugs And Devices Market Concentration

Market Opportunities and Future Outlook

White-space is most visible where policy is steering care delivery toward prevention, digital management, and standardized primary-care coverage, even as adoption remains uneven outside tier-1 cities. The 15th Five-Year National Health Plan, approved in June 2026, prioritizes integration of services and prevention-focused, digitally enabled health management, which supports scalable chronic-disease workflows linking monitoring, therapy titration, and adherence. For device and platform players, this creates room for hospital-to-community transitions such as connected point-of-care glucose management and remote coaching through mainstream channels (including WeChat-based models already used in diabetes care).

Therapy access expansion also opens additional pathways through broader standard-of-care inclusion and more localized supply. A July 2026 update to the National Essential Medicines List added semaglutide, adding an access route alongside reimbursement negotiations and procurement, and reinforcing GLP-1 class relevance for China's diabetes population. In parallel, multinationals have shifted from commercial presence toward capability build-out, including Novo Nordisk’s China Open Innovation Center in Shanghai, with ongoing investments tied to domestic production and quality infrastructure. This supports supply reliability and creates openings for localized device-drug ecosystem partnerships, such as integrated CGM and insulin delivery workflows, tailored to China’s tender and reimbursement realities.

Recent Industry Developments

  • June 2026: Novo Nordisk announced an additional 200 million yuan (approximately 29.4 million USD) investment into its Tianjin production base to expand drug production and injection pen manufacturing capacity. The expansion is designed to add capacity for diabetes therapy demand. The company framed the move as further localization of manufacturing and support for downstream distribution in China.
  • January 2026: Roche - The NMPA approved clinical trials for Roche's oral GLP-1 receptor agonist, RO7795081 (CT-996), for long-term weight management in patients. This step expands Roche's metabolic portfolio and can broaden access to next generation GLP-1 therapies. The approval supports continued research activity and potential later-stage development in China.
  • July 2025: Novo Nordisk - Initiated an 800 million yuan project to expand quality control laboratory facilities at the Tianjin production site, with completion expected by the end of 2026. The capacity upgrade is intended to strengthen product quality assurance and enable higher output. The project also signals continued investment in China to support manufacturing competitiveness.

Table of Contents for China Diabetes Care Drugs And Devices Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing diabetes prevalence & ageing population
    • 4.2.2 Government reimbursement expansion for innovative therapies
    • 4.2.3 Rising adoption of CGM & insulin pump technology
    • 4.2.4 WeChat-based digital adherence platforms
    • 4.2.5 Domestic GLP-1 capacity surge & patent cliffs
    • 4.2.6 Tier-2/3-city retail-pharmacy expansion
  • 4.3 Market Restraints
    • 4.3.1 NRDL price erosion for insulin & devices
    • 4.3.2 Low insulin-pump penetration & education gaps
    • 4.3.3 Data-privacy limits on cloud CGM data
    • 4.3.4 Sensor-chip supply-chain volatility
  • 4.4 Regulatory Landscape
  • 4.5 Technological Outlook
  • 4.6 Porters Five Forces Analysis
    • 4.6.1 Bargaining Power of Suppliers
    • 4.6.2 Bargaining Power of Buyers
    • 4.6.3 Threat of New Entrants
    • 4.6.4 Threat of Substitutes
    • 4.6.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Market Value, USD)

  • 5.1 By Product Type
    • 5.1.1 Devices
    • 5.1.1.1 Monitoring Devices
    • 5.1.1.1.1 Self-Monitoring Blood Glucose Meters
    • 5.1.1.1.2 Continuous Glucose Monitoring Systems
    • 5.1.1.2 Management Devices
    • 5.1.2 Drugs
    • 5.1.2.1 Oral Anti-Diabetic Drugs
    • 5.1.2.2 Insulin Drugs
    • 5.1.2.3 Non-Insulin Injectables
    • 5.1.2.4 Combination Drugs
  • 5.2 By Diabetes Type
    • 5.2.1 Type 1 Diabetes
    • 5.2.2 Type 2 Diabetes
  • 5.3 By Age Group
    • 5.3.1 Adult
    • 5.3.2 Geriatric
    • 5.3.3 Pediatric
  • 5.4 By Distribution Channel
    • 5.4.1 Offline
    • 5.4.2 Online

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Abbott
    • 6.3.2 Medtronic
    • 6.3.3 Novo Nordisk
    • 6.3.4 Sanofi
    • 6.3.5 Eli Lilly
    • 6.3.6 Roche
    • 6.3.7 Dexcom
    • 6.3.8 Insulet
    • 6.3.9 Tandem Diabetes Care
    • 6.3.10 Ypsomed
    • 6.3.11 AstraZeneca
    • 6.3.12 Pfizer
    • 6.3.13 MicroTech Medical
    • 6.3.14 Sinocare
    • 6.3.15 Lepu Medical
    • 6.3.16 Hengrui Medicine
    • 6.3.17 Innovent Biologics
    • 6.3.18 CSPC Pharmaceutical
    • 6.3.19 MicroPort Scientific
    • 6.3.20 Mindray Bio-Medical
    • 6.3.21 Yuwell Medical
    • 6.3.22 Terumo
    • 6.3.23 ARKRAY

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment

Research Methodology Framework and Report Scope

Market Definition and Coverage

This market covers revenues generated in China from diabetes care drugs and diabetes care devices used to manage and monitor blood glucose for people living with diabetes, across hospital, retail, and online purchasing routes.

Scope exclusions: This sizing does not include non-diabetes lifestyle supplements and general wellness wearables that are not used for diabetes monitoring or therapy.

Segmentation Overview
  • By Product Type
    • Devices
      • Monitoring Devices
        • Self-Monitoring Blood Glucose Meters
        • Continuous Glucose Monitoring Systems
      • Management Devices
    • Drugs
      • Oral Anti-Diabetic Drugs
      • Insulin Drugs
      • Non-Insulin Injectables
      • Combination Drugs
  • By Diabetes Type
    • Type 1 Diabetes
    • Type 2 Diabetes
  • By Age Group
    • Adult
    • Geriatric
    • Pediatric
  • By Distribution Channel
    • Offline
    • Online

Data Sources, Market Sizing, and Validation

Desk Research

Desk research was used to build the base demand picture and to keep assumptions tied to real world health system signals in China. We relied on public sources such as the National Health Commission releases, the National Medical Products Administration updates, and the National Healthcare Security Administration policy notes to interpret reimbursement and procurement effects on volumes and pricing.

To translate the demand pool into market value, supporting data was pulled from sources such as the International Diabetes Federation for diabetes prevalence context, peer reviewed clinical and health economics papers for treatment patterns, and China customs and trade statistics for selected device flow signals. We also reviewed company filings, investor presentations, and credible press coverage to verify product availability and channel mix shifts from offline to online. For cross checks on company level revenue and patent activity, we used paid subscriptions that cover company financial intelligence and patent databases. The desk sources listed here are illustrative, and we also reviewed other public documents and databases for data collection, validation, and clarification.

Primary Interviews and Surveys

Primary work was completed through expert interviews and structured surveys with a mix of manufacturers, distributors, hospital and retail channel stakeholders, and clinical voices that track therapy use and monitoring adoption. We used these conversations to confirm pricing direction after procurement rounds, the online share for devices and refills, and realistic adoption timing for newer therapies and monitoring formats across major provinces.

Distribution of primary research fieldwork respondents

Company type Respondent position
Top tier: 35% CXOs: 14%
Mid tier: 49% Functional/Unit leaders: 28%
Smaller Players: 16% Managers: 58%

Market-Sizing & Forecasting

Sizing starts with a top down build in which the treated diabetes population in China is translated into therapy and monitoring demand using diagnosis rates, treatment intensity, and testing frequency patterns. We then value the demand using observed price bands by channel. To keep the overall estimate realistic, we run selective bottom up checks afterward, such as sampled product level ASP times volume for key categories, distributor channel checks for device replenishment, and supplier revenue splits disclosed in public materials.

Key inputs that mattered most in the model include procurement led price resets for insulin and related supplies, share shifts between offline and online channels, uptake rates for continuous monitoring versus self monitoring, insulin delivery format mix, and guideline driven changes in use for newer drug classes. Where data is thin for smaller subcategories, we handle gaps by using proxy ratios from comparable products and then confirming the split with expert feedback before locking the model.

Data Validation & Update Cycle

Validation is done by comparing model outputs against independent checks such as diabetes population direction, channel expansion signals, and category level price movements that should move in line with the revenue trend. Outliers are flagged and reviewed, and if variance cannot be explained by policy timing or a channel mix shift, assumptions are revisited and expert re-contacts are triggered for the specific gap.

Before sign off, the model goes through a multi step analyst review to ensure arithmetic consistency, unit logic, and growth drivers align across drugs and devices. Reports are refreshed annually, and interim updates are made when material events occur, such as large procurement rounds, major regulatory changes, or sudden pricing moves. Right before delivery, a fresh pass is completed so the view reflects the latest available information.

Mordor Intelligence's China Diabetes Care Drugs and Devices Market Estimate Compared With Other Published Estimates

Published market sizes for China diabetes care drugs and devices often do not align because the included product set and channel coverage can vary across studies. Differences also come from how pricing is handled during procurement cycles, what exchange rate timing is used, and whether the estimate is refreshed after key policy events.

Some external numbers expand the scope into broader diabetes treatment spending, including adjacent hospital services or general chronic care packages, which lifts the total. In Mordor Intelligence, the value is counted only for diabetes specific drugs and diabetes devices sold through offline and online channels, then adjusted using procurement timing and category level adoption checks to avoid inflation from out of scope items.

Benchmark comparison

Source Market Size Gaps in Research Methodology
Mordor Intelligence USD 8.98 B (2025)
Industry Research Publisher A USD 45.60 B (2025) Uses a wider diabetes treatment definition that appears to bundle additional care spend beyond drugs and devices, which inflates the addressable value compared with product only revenue.
Market Briefing Publisher B USD 30.00 B (2023) Represents a broad, rounded estimate for overall diabetes treatment spending and does not clearly document price reset timing or channel splits, which can shift totals across years.

The spread in the table mainly comes from scope width and how cleanly product revenues are separated from broader diabetes care spending. By keeping inputs tied to treated patient demand, channel mix, and procurement linked pricing, the estimate stays traceable to steps that can be repeated and checked in each update cycle.

Key Questions Answered in the Report

What is the current value of the China diabetes care drugs and devices market?

The market stands at USD 9.48 billion in 2026 and is forecast to reach USD 12.41 billion by 2031.

Which segment is expanding fastest within the product mix?

Devices, particularly continuous glucose monitoring and insulin pumps, are growing at a 6.28% CAGR through 2031.

How has government procurement affected insulin pricing?

National Volume-Based Procurement lowered median insulin prices by 42.08%, saving USD 2.85 billion across 32,000 medical facilities.

Why is type 1 diabetes expected to grow more quickly than type 2?

Improved diagnostics and higher per-patient technology spending are driving a 6.31% CAGR for the type 1 segment.

What role do online channels play in market distribution?

E-commerce and WeChat-based platforms are projected to expand at 6.42% per year, offering cold-chain delivery and digital adherence support, though offline pharmacies still hold the majority share.

How is the ageing population shaping product development?

More than 200 million citizens aged 65+ require simplified regimens such as once-weekly basal insulin and senior-friendly CGM interfaces, steering innovation toward usability and integrated chronic-condition management.

Page last updated on:

Iran Diabetes Care Devices Market
Market Trends in Japan Diabetes Drugs And Devices
North America Diabetes Care Devices Market Growth
Philippines Diabetes Care Devices Market Size
Market Trends in United States Diabetes Care Drugs And Devices
Market Data for United States Diabetes Devices
Vietnam Diabetes Drugs and Devices Market Trends

China Diabetes Care Drugs And Devices Market Report Snapshots